Nucleic Acid Research Institute
Executive Summary
Kodak leaving R&D joint venture with ICN. Under the exit agreement ICN retains all drugs in research, scientific personnel, lab equipment and facilities. NARI was formed in 1985. Kodak, which recently acquired drug R&D capability with the acquisition of Sterling, previously owned 5% of ICN and 10% of ICN subsidiary Viratek. Those positions were sold in March 1987.